Yunxiao Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yunxiao Zhang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Chujie Bai
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 100142 Beijing, China
1 shared publication - Hairui Wang
Department of Bone and Soft Tissue Oncology, Peking University Cancer Hospital, Inner Mongolia Campus, 010010 Hohhot, China
1 shared publication - Jiayong Liu
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital and Institute, Beijing, China
1 shared publication - Lu Zhang
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 100142 Beijing, China
1 shared publication - Mengmeng Liu
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 100142 Beijing, China
1 shared publication - Ruifeng Xue
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Bone and Soft Tissue Tumor, Peking University Cancer Hospital & Institute, 100142 Beijing, China
1 shared publication
Latest Publications
- Open Access
Lymphatic Mapping to the Inguinal Region in Patients with Lower Extremity Melanoma Undergoing Radical Inguinal Lymph Node Dissection: A Retrospective Cohort Study
Background/Objectives: The anatomical distribution of inguinal lymph node (ILN) metastases may inform research on the extent of therapeutic dissection for lower-limb melanoma. Methods: Fifty-eight patients undergoing radical inguinal lymph node dissection (rILND) were retrospectively evaluated using five anatomical zones. Zone-specific node counts were reaggregated, and exploratory binary logistic regression assessed multiple-zone involvement. Results: The cohort included 48 clinically node-positive and 10 sentinel lymph node biopsy (SLNB)-positive patients. Among 816 mapped ILNs, 149 were positive. Zone I contained 102/149 positive nodes (68.5%); within-zone positivity was 102/303 (33.7%) in zone I, 27/243 (11.1%) in zone II, 13/190 (6.8%) in zone III, 3/39 (7.7%) in zone IV, and 4/41 (9.8%) in zone V. Five patients had no positive mapped ILNs. Zone I contained the only positive node in 19/20 patients (95.0%) and was the sole involved zone in 32/33 patients with single-zone involvement (97.0%). Twenty patients had multiple-zone involvement. In a two-variable complete-case model (50 patients; 18 events), ≥3 positive ILNs remained associated with multiple-zone involvement (adjusted odds ratio, 34.80; 95% confidence interval, 5.88–206.08), whereas extranodal extension did not. Conclusions: This small, selected cohort provides preliminary pathological evidence of preferential inferior-zone involvement. It does not establish sequential spread or the oncological safety of reduced rILND. External and prospective validation are required.
Open AccessLymphatic Mapping to the Inguinal Region in Patients with Lower Extremity Melanoma Undergoing Radical Inguinal Lymph Node Dissection: A Retrospective Cohort Study
Background/Objectives: The anatomical distribution of inguinal lymph node (ILN) metastases may inform research on the extent of therapeutic dissection for lower-limb melanoma. Methods: Fifty-eight patients undergoing radical inguinal lymph node dissection (rILND) were retrospectively evaluated using five anatomical zones. Zone-specific node counts were reaggregated, and exploratory binary logistic regression assessed multiple-zone involvement. Results: The cohort included 48 clinically node-positive and 10 sentinel lymph node biopsy (SLNB)-positive patients. Among 816 mapped ILNs, 149 were positive. Zone I contained 102/149 positive nodes (68.5%); within-zone positivity was 102/303 (33.7%) in zone I, 27/243 (11.1%) in zone II, 13/190 (6.8%) in zone III, 3/39 (7.7%) in zone IV, and 4/41 (9.8%) in zone V. Five patients had no positive mapped ILNs. Zone I contained the only positive node in 19/20 patients (95.0%) and was the sole involved zone in 32/33 patients with single-zone involvement (97.0%). Twenty patients had multiple-zone involvement. In a two-variable complete-case model (50 patients; 18 events), ≥3 positive ILNs remained associated with multiple-zone involvement (adjusted odds ratio, 34.80; 95% confidence interval, 5.88–206.08), whereas extranodal extension did not. Conclusions: This small, selected cohort provides preliminary pathological evidence of preferential inferior-zone involvement. It does not establish sequential spread or the oncological safety of reduced rILND. External and prospective validation are required.